Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Fritsche‐Guenther R[au]:

Search results

Items: 9

1.

Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations.

Fritsche-Guenther R, Zasada C, Mastrobuoni G, Royla N, Rainer R, Roßner F, Pietzke M, Klipp E, Sers C, Kempa S.

Sci Rep. 2018 Jun 15;8(1):9204. doi: 10.1038/s41598-018-27394-1.

2.

An immediate-late gene expression module decodes ERK signal duration.

Uhlitz F, Sieber A, Wyler E, Fritsche-Guenther R, Meisig J, Landthaler M, Klinger B, Blüthgen N.

Mol Syst Biol. 2017 Sep 25;13(9):944. doi: 10.15252/msb.20177986. No abstract available.

3.

An immediate-late gene expression module decodes ERK signal duration.

Uhlitz F, Sieber A, Wyler E, Fritsche-Guenther R, Meisig J, Landthaler M, Klinger B, Blüthgen N.

Mol Syst Biol. 2017 May 3;13(5):928. doi: 10.15252/msb.20177554. Erratum in: Mol Syst Biol. 2017 Sep 25;13(9):944.

4.

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.

Fritsche-Guenther R, Witzel F, Kempa S, Brummer T, Sers C, Blüthgen N.

Oncotarget. 2016 Feb 16;7(7):7960-9. doi: 10.18632/oncotarget.6959.

5.

Analysis of impedance-based cellular growth assays.

Witzel F, Fritsche-Guenther R, Lehmann N, Sieber A, Blüthgen N.

Bioinformatics. 2015 Aug 15;31(16):2705-12. doi: 10.1093/bioinformatics/btv216. Epub 2015 Apr 21.

PMID:
25900918
6.

Network quantification of EGFR signaling unveils potential for targeted combination therapy.

Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, Yan Y, Durek P, Merchant M, Schäfer R, Sers C, Blüthgen N.

Mol Syst Biol. 2013;9:673. doi: 10.1038/msb.2013.29.

7.

Strong negative feedback from Erk to Raf confers robustness to MAPK signalling.

Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer T, Sers C, Blüthgen N.

Mol Syst Biol. 2011 May 24;7:489. doi: 10.1038/msb.2011.27.

8.

Therapeutic potential of CAMPATH-1H in skeletal tumours.

Fritsche-Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser KD, Schlag PM, Kasper HU, Krenn V, Sers C.

Histopathology. 2010 Dec;57(6):851-61. doi: 10.1111/j.1365-2559.2010.03722.x.

PMID:
21166699
9.

De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway.

Fritsche-Guenther R, Noske A, Ungethüm U, Kuban RJ, Schlag PM, Tunn PU, Karle J, Krenn V, Dietel M, Sers C.

Histopathology. 2010 Dec;57(6):836-50. doi: 10.1111/j.1365-2559.2010.03713.x.

PMID:
21166698

Supplemental Content

Loading ...
Support Center